SIMCERE PHARMA (02096) spent 10.1667 million Hong Kong dollars to repurchase 1.49 million shares on November 18th.
Sinopharm (02096) announced that on November 18, 2024, the company invested 1016.67 million...
SIMCERE PHARMA (02096) announced that on November 18, 2024, the company repurchased 1.49 million shares at a cost of 10.167 million Hong Kong dollars. The repurchase price was between 6.71 and 6.98 Hong Kong dollars per share.
Related Articles
New stock news | Goreli Hong Kong stock IPO and the full circulation of domestic unlisted shares approved by the China Securities Regulatory Commission
New stock news | Hailing wisdom element Hong Kong IPO and domestic unlisted shares "full circulation" approved by the China Securities Regulatory Commission for record.
New Stock News | Rujie Electronics' listing on the Hong Kong Stock Exchange IPO and the full circulation of shares not yet listed on the mainland are approved by the China Securities Regulatory Commission.
New stock news | Goreli Hong Kong stock IPO and the full circulation of domestic unlisted shares approved by the China Securities Regulatory Commission
New stock news | Hailing wisdom element Hong Kong IPO and domestic unlisted shares "full circulation" approved by the China Securities Regulatory Commission for record.
New Stock News | Rujie Electronics' listing on the Hong Kong Stock Exchange IPO and the full circulation of shares not yet listed on the mainland are approved by the China Securities Regulatory Commission.
RECOMMEND
Nine Companies With Market Value Over RMB 100 Billion Awaiting, Hong Kong IPO Boom Continues Into 2026
07/02/2026
Hong Kong IPO Cornerstone Investments Surge: HKD 18.52 Billion In First Month, Up More Than 13 Times Year‑On‑Year
07/02/2026
Over 400 Companies Lined Up For Hong Kong IPOs; HKEX Says Market Can Absorb
07/02/2026
